本文已被:浏览 465次 下载 378次
Received:February 23, 2022 Published Online:September 20, 2022
Received:February 23, 2022 Published Online:September 20, 2022
中文摘要: 目的 比较亚胺培南西司他丁钠或美罗培南治疗早期肺癌合并重症肺部感染患者的有效性、安全性和经济性,为临床治疗提供参考。方法 回顾性分析南京市胸科医院2016年6月至2021年6月诊断为重症肺部感染的并且使用亚胺培南西司他丁钠或美罗培南的186例早期肺癌患者的临床资料。将使用美罗培南的患者列为美罗培南组(n=115),使用亚胺培南西司他丁钠的患者列为亚胺培南组(n=71)。观察并比较两组临床疗效、病原菌清除率、院内全因死亡率、炎症因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)]水平,药物不良反应发生率,抗感染药物费用、总药费、全部总费用和成本效果比(C/E)。结果 两组患者的临床总有效率、病原菌清除率、住院死亡率,治疗前后TNF-α、IL-6、CRP水平比较差异无统计学意义(P>0.05)。美罗培南组抗感染药物费用、总药费、总费用低于亚胺培南组,差异有统计学意义(P<0.01)。美罗培南组患者的C/E低于亚胺培南组。结论 美罗培南和亚胺培南西司他丁治疗早期肺癌合并重症肺部感染患者在临床疗效、降低血清炎症因子水平、住院死亡率和药物不良反应发生率方面相当,但是美罗培南具有更好的经济性。
Abstract:Objective To compare the efficacy, safety and economics of imipenem cilastatin sodium or meropenem in the treatment of patients with early lung cancer complicated with severe pulmonary infection, to provide reference for clinical treatment. Methods The clinical data of 186 patients with early stage lung cancer who were diagnosed with severe pulmonary infection from June 2016 to June 2021 in Nanjing Chest Hospital and were treated with imipenem, cilastatin sodium or meropenem were retrospectively analyzed. Patients using meropenem were classified as meropenem group (n=115),and patients using imipenem cilastatin sodium were classified as imipenem group(n=71). The clinical efficacy, pathogen clearance rate, all-cause mortality in hospital, inflammatory factor level[C-reactive protein(CRP), interleukin-6(IL-6), tumor necrosis factor α(TNF-α)],adverse drug reaction rate, anti-infective drug cost, total drug cost, total cost and cost-effectiveness(C/E) were observed and compared between the two groups. Results There was no significant difference in the clinical total effective rate, pathogen clearance rate, in-hospital mortality rate, TNF-α, IL-6 and CRP levels before and after treatment between the two groups(P>0.05). The cost of anti-infective drugs, total drug cost and total cost in the meropenem group were lower than those in the imipenem group(P<0.01). The C/E of patients in the meropenem group was lower than that in the imipenem group. Conclusion Meropenem and imipenem-cilastatin in the treatment of patients with early-stage lung cancer complicated with severe pulmonary infection are equivalent in terms of clinical efficacy, reduction of serum inflammatory factor levels, in-hospital mortality and incidence of adverse drug reactions, but meropenem has better economics.
文章编号: 中图分类号:R734.2 R563.1 文献标志码:B
基金项目:南京市卫计委科技发展资金立项一般性课题(YKK17184)
Author Name | Affiliation |
WANG Fang, ZHOU Qiu-yun, LU Tao | Department of Pharmacy, Nanjing Chest Hospital, Nanjing, Jiangsu 210029,China |
Author Name | Affiliation |
WANG Fang, ZHOU Qiu-yun, LU Tao | Department of Pharmacy, Nanjing Chest Hospital, Nanjing, Jiangsu 210029,China |
引用文本: